SCHEMBL16459248

SCHEMBL16459248

O=C(O)NCCN1CCC(CNC(=O)c2ccc3c(c2)OC(F)(F)O3)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMYD3 Q9H7B4 5/20 0.49
KCNH2 Q12809 3/20 0.46
CACNA1I Q9P0X4 3/20 0.46
HPGD P15428 1/20 0.46
HDAC6 Q9UBN7 4/20 0.45
KDM1A O60341 2/20 0.45
CACNA1H O95180 1/20 0.45
CYP2D6 P10635 1/20 0.45
CHRM2 P08172 1/20 0.44
CHRM1 P11229 1/20 0.44
DHODH Q02127 1/20 0.44
SLC6A2 P23975 1/20 0.44
SLC6A4 P31645 1/20 0.44
MCHR1 Q99705 1/20 0.43
HTR4 Q13639 1/20 0.43
HDAC3 O15379 2/20 0.43
HDAC4 P56524 2/20 0.43
HDAC1 Q13547 2/20 0.43
HDAC7 Q8WUI4 2/20 0.43
HDAC2 Q92769 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8370950 0.88 SMYD3 (0.53) SMYD3KCNH2CACNA1IHDAC6DHODH
SCHEMBL14769940 0.88 HTR4 (0.52) SMYD3KCNH2CACNA1IDHODHMCHR1
SCHEMBL4271194 0.86 KCNH2 (0.48) SMYD3KCNH2CACNA1IHPGDCACNA1H
SCHEMBL14763383 0.74 CHRM4 (0.62) HDAC6KDM1ASLC6A2SLC6A4MCHR1
SCHEMBL17841326 0.73 KCNH2 (0.53) KCNH2CACNA1IHDAC6CACNA1HCYP2D6
SCHEMBL4278328 0.72 KDM4E (0.43) SMYD3KCNH2CACNA1IDHODHMCHR1
SCHEMBL16458809 0.72 BCL3 (0.52) KCNH2CACNA1HCYP2D6MCHR1HTR4
SCHEMBL16459142 0.71 KCNH2 (0.56) KCNH2CACNA1IHDAC6CACNA1HCYP2D6
SCHEMBL22367079 0.69 NR1H4 (0.53) HPGDHDAC6SLC6A2SLC6A4HDAC3
SCHEMBL24076507 0.69 SLC6A2 (0.69) SLC6A2SLC6A4MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140011996-A1 N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2014-01-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140011996-A1 N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CACNA1G, CACNA1H, CACNA1B SMYD3 3801/4885KCNH2 60/4885CACNA1I 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.